SUNNYVALE, Calif.--(BUSINESS WIRE)--Adeza (NASDAQ:ADZA) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation covering Gestiva™, the company’s therapeutic candidate for the prevention of preterm birth in women with a history of preterm delivery. If Gestiva is approved, Orphan Drug designation provides the opportunity for seven years of U.S. market exclusivity.
